PARP7 Inhibitor Compounds for Restoring Type I Interferon Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are currently no approved PARP7 inhibiting pharmaceuticals, limiting the potential for effective cancer treatment targeting this enzyme.
Innovation Solution
Development of compounds and pharmaceutical compositions that inhibit PARP7, including specific structural elements and functional groups to enhance their pharmaceutical properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no PARP7 inhibiting pharmaceuticals are developed, then the current lack of treatment options is maintained, but cancer treatment effectiveness remains limited
Solution Approach 1:
The patent segments the broad ART superfamily of enzymes into specific targetable members, focusing on PARP7 as a distinct therapeutic target. This segmentation allows for selective inhibition of PARP7 without affecting other PARP family members, enabling tailored cancer treatments that address specific molecular pathways involved in tumor survival and stress responses
Solution Approach 2:
The patent employs parameter changes by developing compounds with specific molecular structures (Formula I with varying R1-R7, R9-R18 substituents) that optimize binding affinity to PARP7. By systematically varying chemical parameters such as substituent groups, ring structures, and molecular weight, the invention achieves enhanced inhibitory potency and selectivity for PARP7 over other enzymes
2Reliability
If PARP7 inhibitors are developed with complex structural elements to enhance pharmaceutical properties, then inhibition effectiveness improves, but compound complexity increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and substituent patterns at particular positions within the core molecular structure. For example, specific R1-R7 substituents at defined positions on the ring system provide localized interactions with PARP7 binding site residues, enhancing inhibition effectiveness while maintaining overall structural manageability through targeted rather than universal complexity
Solution Approach 2:
The patent creates composite molecular structures by combining heterocyclic core systems with various substituent moieties (aromatic rings, aliphatic chains, heteroatom-containing groups). These composite structures integrate multiple functional elements that collectively achieve high PARP7 binding affinity and selectivity, while the modular nature of the composite design allows for systematic optimization without excessive overall complexity
Data Source
AI summary
Provided herein is a compound of Formula I:or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.